Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Wile, a wellness brand focused on midlife women's health, is set to launch four herbal supplement capsules at Walgreens this month. Aimed at women aged 40+, these products target common hormonal symptoms like stress and night sweats. Wile's holistic approach, developed with naturopathic doctors, includes the 40+ Perimenopause Support, 40+ Period Support, Hot Flash, and Women’s Stress supplements, all retailing for $39.99. This partnership highlights Wile's goal to enhance visibility and accessibility in midlife women’s health, reinforcing the role of community pharmacies in healthcare.
Walgreens Boots Alliance (WBA) will announce its fiscal 2022 third quarter earnings on June 30, 2022, at 7 a.m. ET, followed by a conference call at 8:30 a.m. ET. The event will be available live on the WBA investor relations website, with a replay accessible for 12 months. WBA, a global leader in pharmacy and healthcare, operates around 13,000 locations across the U.S., Europe, and Latin America, committed to improving health services and promoting sustainability. The company employs over 315,000 people and has a diverse portfolio of consumer and healthcare-focused brands.
Walgreens has announced the winners of its 12th annual Expressions by Walgreens national art challenge, with nearly 3,400 high school entries in visual arts, spoken word, and media arts. Awards are given to top entries in each category, along with a People's Choice award and new Teachers' Champion awards recognizing educators supporting students. Since 2009, the initiative has engaged over one million students and awarded more than $350,000 in prizes, emphasizing Walgreens' commitment to community health and youth self-expression.
Summary not available.
Walgreens Boots Alliance has sold 6.0 million shares of AmerisourceBergen Corporation for $900 million, reducing its stake from 28.1% to 25.2%. The proceeds will primarily be allocated for debt paydown and supporting strategic initiatives. Despite the sale, Walgreens maintains its long-term partnership with AmerisourceBergen, ensuring ongoing collaboration. This strategic move aims to optimize capital allocation and enhance the company's balance sheet, reflecting a commitment to shareholder value.
Walgreens has reached a $683 million settlement with the State of Florida regarding opioid medication distribution. This includes $620 million to be paid over 18 years and a $63 million one-time payment for legal fees. The settlement does not imply any wrongdoing by Walgreens. The funds will assist Florida in combating opioid addiction. Walgreens emphasizes its commitment to education, safe disposal of medications, and preventive actions against misuse, having halted self-distribution of opioids since 2014.
Walgreens has appointed three new senior executives: Linh Peters as SVP and Chief Marketing Officer, Luke Rauch as SVP and Chief Merchandising Officer, and Bala Visalatha as SVP and Chief Product Officer. These appointments, effective May, aim to leverage their extensive retail experience to drive growth and enhance customer experiences. Tracey Brown, President of Retail Products, expressed confidence in their ability to innovate and transform Walgreens' offerings to meet evolving consumer needs.
Walgreens Boots Alliance (WBA) has declared a quarterly dividend of 47.75 cents per share, maintaining the same amount as the previous quarter but marking a 2.1% increase from the year-ago quarter. The dividend is payable on June 10, 2022, to stockholders of record as of May 20, 2022. WBA has a strong dividend history, having paid dividends for 358 consecutive quarters and raised them for 46 consecutive years, reflecting the company’s commitment to returning value to shareholders.
Walgreens Boots Alliance (Nasdaq: WBA) and VillageMD plan to open over 10 new Village Medical at Walgreens locations in Massachusetts by early 2023, creating 350 full-time jobs. The first practice opens in Quincy this May. This initiative aims to enhance access to coordinated primary care and pharmacy services for Medicare beneficiaries with chronic conditions. The collaboration will expand to over 600 practices in more than 30 markets by 2025. Both companies are focused on improving patient care through technology and a streamlined healthcare experience.
Hey Humans, an eco-conscious personal care brand, expands its reach by launching products at over 6,000 Walgreens locations nationwide and on walgreens.com. Launched in 2021, the brand is committed to sustainability, with a product line that is 99% plastic-free, vegan, and cruelty-free. Items include deodorants priced at $6.99 and body washes at $7.99, designed to offer clean personal care without compromising on environmental responsibility. The partnership aims to make sustainable personal care accessible to a broader audience.